## Contents

**Chapter 1**  
General introduction and rationale for this thesis  

**Chapter 2**  
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial  
*Diabetes Care* 2009;32:762-768  

**Chapter 3**  
One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress  
*Atherosclerosis* 2010;212:223-229  

**Chapter 4**  
One-year exenatide and insulin glargine treatment improves prandial beta-cell response in metformin treated patients with type 2 diabetes  
*Diabetes Obes Metab* (Submitted for publication)  

**Chapter 5**  
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition  
*Diabetes Care* 2010;33:1734-1737  

**Chapter 6**  
Effects of exenatide on measures of beta-cell function after 3-years in metformin-treated patients with type 2 diabetes  
*Diabetes Care* (Accepted for publication)  

**Chapter 7**  
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes  
*Diabetes Obes Metab* 2011;13:374-377  

**Chapter 8**  
Incretin mimetics as a novel therapeutic option for hepatic steatosis  
*Liver Int* 2006;26:1015-1017
Chapter 9
Summary and conclusion 139

Chapter 10
Samenvatting voor de geïnteresseerde leek 166
List of abbreviations 174
Affiliation of co-authors 176
List of publications 178
Dankwoord/Acknowledgments 181
Curriculum vitae 185